PROMISES FOR TREATING COLON CANCER PATIENTS WITH BRAF GENE MUTATION
Colon cancer represents a heterogenous disease group, which differ by cancerogenesis mechanisms, molecular alterations, prognosis and treatment possibilities. In modern clinical practice assessment of KRAS and NRAS genes status is already necessary in order to prescribe anti-EGFR treatment for metas...
Main Authors: | M. Yu. Fedyanin, A. A. Tryakin, S. A. Tjulandin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
“ABV-press” Publishing house”, LLC
2015-02-01
|
Series: | Тазовая хирургия и онкология |
Subjects: | |
Online Access: | https://ok.abvpress.ru/jour/article/view/34 |
Similar Items
-
The possibilities of therapy of patients with metastatic colorectal cancer with <i>BRAF</i> V600E mutation. Clinical cases
by: Elizaveta M. Polyanskaya, et al.
Published: (2023-05-01) -
BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in <i>BRAF</i>-Mutated Metastatic Colorectal Cancer—A Case Series Study <i>Target Therapy of</i> BRAF-<i>Mutated mCRC</i>
by: Jen-Hao Yeh, et al.
Published: (2021-12-01) -
The Impact of Drug–Drug Interactions on the Toxicity Profile of Combined Treatment with BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma
by: Silvia Mezi, et al.
Published: (2023-09-01) -
Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
by: Paola Savoia, et al.
Published: (2020-12-01) -
Defining the Criteria for Reflex Testing for <i>BRAF</i> Mutations in Cutaneous Melanoma Patients
by: Sarah Zhou, et al.
Published: (2021-05-01)